Stockreport

Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa [Yahoo! Finance]

Ocugen, Inc.  (OCGN) 
PDF Topline Phase 3 data expected in 1Q 2027, advancing OCU400 towards potential approval in 2027 as a treatment option for early- to late-stage RP Positive long-term, 3- [Read more]